Warning: The NCBI web site requires JavaScript to function. more...
Pilot phase III immunotherapy study in early-stage breast cancer patients using oxidized mannan-MUC1 [ISRCTN71711835].
Apostolopoulos V, Pietersz GA, Tsibanis A, Tsikkinis A, Drakaki H, Loveland BE, Piddlesden SJ, Plebanski M, Pouniotis DS, Alexis MN, McKenzie IF, Vassilaros S.
Breast Cancer Res. 2006;8(3):R27. Epub 2006 Jun 15.
Related citations
Mannan mucin-1 peptide immunization: influence of cyclophosphamide and the route of injection.
Karanikas V, Thynne G, Mitchell P, Ong CS, Gunawardana D, Blum R, Pearson J, Lodding J, Pietersz G, Broadbent R, Tait B, McKenzie IF.
J Immunother. 2001 Mar-Apr;24(2):172-83.
Survival in early breast cancer patients is favorably influenced by a natural humoral immune response to polymorphic epithelial mucin.
von Mensdorff-Pouilly S, Verstraeten AA, Kenemans P, Snijdewint FG, Kok A, Van Kamp GJ, Paul MA, Van Diest PJ, Meijer S, Hilgers J.
J Clin Oncol. 2000 Feb;18(3):574-83.
Antibody and T cell responses of patients with adenocarcinoma immunized with mannan-MUC1 fusion protein.
Karanikas V, Hwang LA, Pearson J, Ong CS, Apostolopoulos V, Vaughan H, Xing PX, Jamieson G, Pietersz G, Tait B, Broadbent R, Thynne G, McKenzie IF.
J Clin Invest. 1997 Dec 1;100(11):2783-92.
Recombinant vaccinia virus encoding human MUC1 and IL2 as immunotherapy in patients with breast cancer.
Scholl SM, Balloul JM, Le Goc G, Bizouarne N, Schatz C, Kieny MP, von Mensdorff-Pouilly S, Vincent-Salomon A, Deneux L, Tartour E, Fridman W, Pouillart P, Acres B.
J Immunother. 2000 Sep-Oct;23(5):570-80.
Mannan-MUC1-pulsed dendritic cell immunotherapy: a phase I trial in patients with adenocarcinoma.
Loveland BE, Zhao A, White S, Gan H, Hamilton K, Xing PX, Pietersz GA, Apostolopoulos V, Vaughan H, Karanikas V, Kyriakou P, McKenzie IF, Mitchell PL.
Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):869-77.
Breast cancer immunotherapy: current status and future prospects.
Apostolopoulos V, McKenzie IF, Pietersz GA.
Immunol Cell Biol. 1996 Oct;74(5):457-64. Review.
Phase I immunotherapy with a modified vaccinia virus (MVA) expressing human MUC1 as antigen-specific immunotherapy in patients with MUC1-positive advanced cancer.
Rochlitz C, Figlin R, Squiban P, Salzberg M, Pless M, Herrmann R, Tartour E, Zhao Y, Bizouarne N, Baudin M, Acres B.
J Gene Med. 2003 Aug;5(8):690-9.
Dendritic cell vaccine immunotherapy of cancer targeting MUC1 mucin.
Kontani K, Taguchi O, Ozaki Y, Hanaoka J, Sawai S, Inoue S, Abe H, Hanasawa K, Fujino S.
Int J Mol Med. 2003 Oct;12(4):493-502.
Vaccination of high-risk breast cancer patients with mucin-1 (MUC1) keyhole limpet hemocyanin conjugate plus QS-21.
Gilewski T, Adluri S, Ragupathi G, Zhang S, Yao TJ, Panageas K, Moynahan M, Houghton A, Norton L, Livingston PO.
Clin Cancer Res. 2000 May;6(5):1693-701.
Human MUC1 mucin: a multifaceted glycoprotein.
von Mensdorff-Pouilly S, Snijdewint FG, Verstraeten AA, Verheijen RH, Kenemans P.
Int J Biol Markers. 2000 Oct-Dec;15(4):343-56. Review.
Advances of MUC1 as a target for breast cancer immunotherapy.
Yang E, Hu XF, Xing PX.
Histol Histopathol. 2007 Aug;22(8):905-22. Review.
Therapeutic aspects of polymorphic epithelial mucin in adenocarcinoma.
Miles DW, Taylor-Papadimitriou J.
Pharmacol Ther. 1999 Apr;82(1):97-106. Review.
A phase II study of Tg4010 (Mva-Muc1-Il2) in association with chemotherapy in patients with stage III/IV Non-small cell lung cancer.
Ramlau R, Quoix E, Rolski J, Pless M, Lena H, Lévy E, Krzakowski M, Hess D, Tartour E, Chenard MP, Limacher JM, Bizouarne N, Acres B, Halluard C, Velu T.
J Thorac Oncol. 2008 Jul;3(7):735-44. Erratum in: J Thorac Oncol. 2008 Aug;3(8):941.
Phase I study of a MUC1 vaccine composed of different doses of MUC1 peptide with SB-AS2 adjuvant in resected and locally advanced pancreatic cancer.
Ramanathan RK, Lee KM, McKolanis J, Hitbold E, Schraut W, Moser AJ, Warnick E, Whiteside T, Osborne J, Kim H, Day R, Troetschel M, Finn OJ.
Cancer Immunol Immunother. 2005 Mar;54(3):254-64. Epub 2004 Sep 14.
Humoral immune responses to MUC1 in women with a BRCA1 or BRCA2 mutation.
Hermsen BB, Verheijen RH, Menko FH, Gille JJ, van Uffelen K, Blankenstein MA, Meijer S, van Diest PJ, Kenemans P, von Mensdorff-Pouilly S.
Eur J Cancer. 2007 Jul;43(10):1556-63. Epub 2007 May 25.
MUC1 cross-reactive Gal alpha(1,3)Gal antibodies in humans switch immune responses from cellular to humoral.
Apostolopoulos V, Osinski C, McKenzie IF.
Nat Med. 1998 Mar;4(3):315-20.
Overview of resistance to systemic therapy in patients with breast cancer.
Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN.
Adv Exp Med Biol. 2007;608:1-22. Review.
Adoptive immunotherapy for pancreatic cancer: cytotoxic T lymphocytes stimulated by the MUC1-expressing human pancreatic cancer cell line YPK-1.
Kawaoka T, Oka M, Takashima M, Ueno T, Yamamoto K, Yahara N, Yoshino S, Hazama S.
Oncol Rep. 2008 Jul;20(1):155-63.
Induction of humoral and cellular responses in cynomolgus monkeys immunised with mannan-human MUC1 conjugates.
Vaughan HA, Ho DW, Karanikas VA, Ong CS, Hwang LA, Pearson JM, McKenzie IF, Pietersz GA.
Vaccine. 1999 Jun 4;17(20-21):2740-52.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on